Get to the root of your digestive issues with gut-brain therapy techniques that help you self-manage your gut symptoms in just 6-weeks.

IBS, functional dyspepsia, functional constipation, and functional heartburn are now classified as gut-brain disorders - conditions driven by miscommunication between the gut and brain. The same gut-brain dysfunction also explains why many people with IBD continue to experience pain, constipation, or diarrhea even when their disease is in remission.
When the gut and brain fail to communicate properly, the body can misinterpret normal digestive processes as pain or discomfort. This heightened sensitivity, known as visceral hypersensitivity, can make the gut more reactive and contribute to gastrointestinal symptoms.
Nerva combines evidence-based gut-brain therapy techniques with real human support to help you self-manage symptoms, rebuild confidence, and get back to living fully.
The Nerva program was co-founded by Dr. Simone Peters, who ran a clinical trial with Monash University that found gut-brain therapy therapy worked just as well as the Low FODMAP diet in helping you participants well with and self-manage IBS.



Gut-brain therapy techniques targets the source of the problem: oversensitive nerves in the gut.
Gut-brain therapy techniques teaches you how to address this miscommunication between the gut and brain.
Gut-brain therapy techniques has been shown to help with constipation, diarrhea and mixed IBS.
Studies have shown gut-brain therapy techniques can help you achieve long-lasting IBS management.




Answer questions about you and your gut history to see if Nerva can work for you.

Daily gut-brain sessions, educational content, and goal oriented progress, tailored to your preferences.

Learn skills that can help you teach your brain to ignore false alarms from the gut triggered by food and stress.

Live the life you want, free from the control of digestive diseases.
.png)

Open-world discovery: Discover the beautiful island of Edenzo, complete with spectacular beaches, scenic highways, and hidden secrets. Wide range of automobiles
Open-world exploration: Discover the lovely island of Edenzo, finished with breathtaking beaches, scenic routes, and hidden secrets. Wide range of cars test drive unlimited 1 pc download highly compressed
Text: Test Ride Boundless 1 PC Acquire: A Very Compact Driving Adventure Happen to be one a speed video game fan searching for a exhilarating adventure on ones PC? Search no more than Trial Drive Boundless 1, a classic title that still provides a strike nowadays. In the article, we shall explore the universe of Test Cruise Unrestricted 1 and supply people with a comprehensive guide on how to acquire the game on ones PC, highly compact for optimal functionality. Exactly what is Trial Drive Unlimited 1? Trial Cruise Unlimited 1 is an sandbox driving title developed by Eden Games and distributed by Atari. Launched in 2006, the title permits gamers to explore the beautiful island of Edenzo, complete with stunning beaches, scenic streets, and challenging speed courses. With a huge free world to navigate, a broad variety of automobiles to select from, and various video game modes, Test Cruise Boundless 1 provides an absorbing game playing journey that’s difficult to place down. Key Attributes of Test Cruise Boundless 1 Search no more than Trial Drive Boundless 1,
Article: Test Drive Unlimited 1 PC Grab: A Highly Compact Racing Adventure Will you a racing game enthusiast hunting for a thrilling experience on your PC? Search no more than Test Drive Unlimited 1, a classic game that still delivers a punch today. In this piece, we'll examine the world of Test Drive Unlimited 1 and give you with a comprehensive manual on how to download the game on your PC, extremely compressed for optimal performance. What is Test Drive Unlimited 1? Test Drive Unlimited 1 is an open-world racing game developed by Eden Games and released by Atari. Released in 2006, the game permits players to traverse the gorgeous island of Edenzo, complete with amazing beaches, scenic roads, and challenging racing tracks. With a vast open world to explore, a wide range of cars to select from, and various game options, Test Drive Unlimited 1 offers an immersive gaming adventure that’s tough to put down. Major Features of Test Drive Unlimited 1 Trial Cruise Unlimited 1 is an sandbox driving

"Hi, it's Alex, one of the founders of Nerva alongside Chris and Dr. Simone Peters.
We designed Nerva to help people with gut-brain disorders get back to a happy, normal life, free of flare-up worries. We're so proud of the fact that we've already helped over 300,000 people live better. Yet, we understand Nerva may not work for some people which is why we have a 100% money back guarantee.
If you finish your 6-week program and think Nerva hasn't helped you manage your symptoms, simply email support for a full refund of the Nerva program."
- Alex Naoumidis, Co-Founder and Co-CEO, Mindset Health

Based on studies that helped 3 in 4 people manage their gut symptoms.
15 minutes a day for 6 weeks. Short and relaxing sessions that fit with your schedule.
Discover helpful and calming flare-up exercises, like our deep breathing techniques.
Listen anytime and anywhere (home, office, couch, you name it).
Learn about gut-brain disorders with a range of easy to understand in-app articles.
Say bye to bots. We have real Nerva team members ready to help!
1) Anderson, Ellen J. BNutSci, MDiet1,2; Peters, Simone L. BSc (Psychophysiology) (Hons), PhD1; Gibson, Peter R. MBBS(Hons), MD1,2; Halmos, Emma P. BNutDiet, PGradDipBSc, PhD1,2. Comparison of Digitally Delivered Gut-Directed Hypnotherapy Program With an Active Control for Irritable Bowel Syndrome. The American Journal of Gastroenterology 120(2):p 440-448, February 2025. | DOI: 10.14309/ajg.0000000000002921 2) Peters, S. L., Yao, C. K., Philpott, H., Yelland, G. W., Muir, J. G., & Gibson, P. R. (2016). Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome. Alimentary pharmacology & therapeutics, 44(5), 447–459. https://doi.org/10.1111/apt.13706